Rox Medical has announced that, with the enrolment of the first German patient, it has crossed the halfway point of its CONTROL-HTN trial—an international, multicentre, randomised controlled hypertension trial of the Rox Flow procedure. The procedure creates a small connection between artery and vein in the upper leg for the treatment of resistant hypertension.
A press release reports that the Rox Flow procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. It reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system.
“We have been thrilled by the enthusiasm of the clinical centres in the CONTROL-HTN trial and congratulate the Berlin physicians on the first enrollment in Germany,” commented ROX chief executive officer Rodney Brenneman.
